For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co IncMRK 1%.
The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria. That’s two more strains than Prevnar 13, a product from rival Pfizer IncPFE 1.05%.
